- Home
- HFFG vs GOSS Comparison
HFFG vs GOSS Comparison
Compare HFFG & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFFG
- GOSS
- Stock Information
- Founded
- HFFG N/A
- GOSS 2015
- Country
- HFFG United States
- GOSS United States
- Employees
- HFFG N/A
- GOSS N/A
- Industry
- HFFG Food Distributors
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- HFFG Consumer Discretionary
- GOSS Health Care
- Exchange
- HFFG Nasdaq
- GOSS Nasdaq
- Market Cap
- HFFG 180.3M
- GOSS 212.9M
- IPO Year
- HFFG N/A
- GOSS 2019
- Fundamental
- Price
- HFFG $3.54
- GOSS $0.70
- Analyst Decision
- HFFG
- GOSS Strong Buy
- Analyst Count
- HFFG 0
- GOSS 5
- Target Price
- HFFG N/A
- GOSS $9.20
- AVG Volume (30 Days)
- HFFG 43.6K
- GOSS 951.6K
- Earning Date
- HFFG 11-12-2024
- GOSS 11-07-2024
- Dividend Yield
- HFFG N/A
- GOSS N/A
- EPS Growth
- HFFG N/A
- GOSS N/A
- EPS
- HFFG N/A
- GOSS N/A
- Revenue
- HFFG $1,177,258,000.00
- GOSS $105,322,000.00
- Revenue This Year
- HFFG $4.57
- GOSS N/A
- Revenue Next Year
- HFFG $3.25
- GOSS N/A
- P/E Ratio
- HFFG N/A
- GOSS N/A
- Revenue Growth
- HFFG 1.53
- GOSS N/A
- 52 Week Low
- HFFG $2.46
- GOSS $0.50
- 52 Week High
- HFFG $5.91
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- HFFG 55.84
- GOSS 25.81
- Support Level
- HFFG $3.33
- GOSS $0.66
- Resistance Level
- HFFG $3.53
- GOSS $0.92
- Average True Range (ATR)
- HFFG 0.14
- GOSS 0.05
- MACD
- HFFG 0.00
- GOSS -0.02
- Stochastic Oscillator
- HFFG 80.95
- GOSS 13.23
About HFFG HF Foods Group Inc.
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The Company's business consists of one operating segment; HF Group, which operates solely in the United States. The Company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.